Mangoceuticals Inc. Watch

from 8-K 27 pages Securities Purchase Agreement

from 8-K 5 pages Note Purchase Agreement

from 8-K 24 pages Mangoceuticals, Inc. Amended and Restated Executive Employment Agreement Jacob Cohen Chief Executive Officer

from 8-K 5 pages Parent Subsidiary Contribution Agreement

from 8-K 24 pages Patent Purchase Agreement

from 8-K 8 pages December 2, 2024 Personal and Confidential Mangoceuticals, Inc. 15110 Dallas Parkway, Suite 600 Dallas, Texas 75248 Attn: Jacob D. Cohen – Chief Executive Officer 1. Services. Greentree Agrees to Perform the Following Services: (A) Assist the Company With Compliance Filings for the Quarters Ended March 31, 2025, June 30, 2025, September 30, 2025, and One Annual Report for the Year Ended December 31, 2024, Including the Consolidation Structure and Entries as Well as Assist With US Gaap Footnotes; (B) Review and Advise the Company on All Documents and Accounting Systems Relating to Its Finances and Transactions, With the Purpose of Bringing Such Documents and Systems Into Compliance With US Gaap or Disclosures Required by SEC; (C) Provide Necessary Consulting Services and Support as a Liaison for the Company to Third-Party Service Providers, Including Coordination Amongst the Company and Their Related Attorneys, Cpas and the Transfer Agent. (D) Prepare and File the Company’s Tax Return With the Irs for the 2024 Tax Year. 2. Fees. the Company Agrees to Pay Greentree for Its Services Professional Service Fees Consisting of $40,000 in Cash and 40,000 Shares of the Company’s Restricted Common Stock (The “Service Fee” or “Securities”) During the Term, Payable as Follows: (A) a Payment of $20,000 Shall Be Made in Cash via Wire on or Before December 31, 2024; (B) a Payment of $20,000 Shall Be Made in Cash via Wire on or Before March 31, 2025;

from 8-K 8 pages Consulting Agreement

from 8-K 10 pages Promissory Note

from 8-K 11 pages Master Distribution Agreement

from 8-K 6 pages Omnibus Amendment Agreement No. 1

from 8-K 21 pages Patent Purchase Agreement

from 8-K 21 pages Registration Rights Agreement

from 8-K 21 pages Registration Rights Agreement

from 8-K 35 pages Equity Purchase Agreement

from 8-K 31 pages Securities Purchase Agreement

from 8-K 34 pages Mangoceuticals, Inc. Amended and Restated 2022 Equity Incentive Plan Originally Adopted by the Board of Directors On: August 31, 2022 Approved and Ratified by the Stockholders On: August 31, 2022 Amended by the Board of Directors on February 26, 2024 and the Stockholders on March 25, 2024

from 8-K ~1 page First Amendment to Mangoceuticals, Inc. 2022 Equity Incentive Plan

from 8-K 12 pages Mangoceuticals, Inc. 2022 Equity Incentive Plan Stock Option Agreement

from S-1 11 pages Mangoceuticals, Inc. 2022 Equity Incentive Plan Notice of Restricted Stock Grant

from S-1 5 pages Advisor Agreement